Autoinjectors Market Statistics, 2027
The global autoinjectors market was valued at $ 1,509.0 million in 2019, and is expected to reach $ 5,732.6 million by 2027, with a CAGR of 18.1% during the forecast period. An autoinjector is a syringe with a spring-charged needle having a pre-charged dosage of drugs. The system triggers and administers a measured dosage of a drug, when pressed into the body with a sliding motion. Autoinjectors are widely used for epinephrine self-administration (to prevent anaphylaxis); by migraine sufferers (for immediate pain relief); or for medical and emergency treatments. Auto-injectors provide multiple benefits such as decreasing needle-related phobia disorder, decreasing risks of needle stuck accidents, ensuring dosage quality continuity, and helping increase effectiveness.
The autoinjector market is expected to register a substantial growth in the future, owing to rise in anaphylaxis cases. In addition, rise in R&D efforts by companies to develop simple, cost effective, and new technology based autoinjectors for treatment of chronic diseases such as rheumatoid arthritis and multiple sclerosis is expected to boost the market growth during the forecast period.
However, availability of alternative treatment options is anticipated to hamper the market growth during the forecast period. On the contrary, a fundamental shift from biologics to biosimilars, which are delivered through autoinjectors are anticipated to provide lower cost options to patients opting for prolonged treatment. These factors are expected to provide remunerative opportunities for the market players.
Global Autoinjectors Market Segmentation
The autoinjectors market is segmented on the basis of type, application, end user, and region. By type, it is categorized into disposable and reusable autoinjectors. On the basis of application, it is divided into rheumatoid arthritis, multiple sclerosis, anaphylaxis, and others. By end user, it is categorized into home care settings and hospitals & clinics. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Depending on type, the market is categorized into disposable and reusable autoinjectors. The disposable autoinjectors segment dominated the global market in 2019, and is anticipated to continue this trend during the forecast period. The key factors such as rise in prevalence of anaphylaxis and rheumatoid arthritis and further increasing patient preference for autoinjectors drives the growth of this treatment segment.The use of autoinjectors has benefits such as rapid action and simplified administration
On the basis of application, the market is categorized into rheumatoid arthritis, multiple sclerosis, anaphylaxis, and others. The anaphylaxis segment held a dominant position in the market, accounting for about 38.5% share of the global autoinjectors market in 2019.
By end user, the market is categorized into home care settings and hospitals & clinics. The home care settings segment held a dominant portion in the market, accounting for about 62.8% share of the global autoinjectors market in 2019.
North America accounted for the largest share in the global autoinjectors market. Asia-Pacific is expected to witness highest growth rate throughout the forecast period. Rise in cases of anaphylaxis; rheumatoid arthritis; and other diseases such as anemia and migraine; and further increase in technological advancements by companies are anticipated to drive the overall market growth.
By Type Segment Review
Depending on type, the market is categorized into disposable and reusable autoinjectors. The disposable autoinjectors segment dominated the global market in 2019, and is anticipated to continue this trend during the forecast period. The key factors such as rise in prevalence of anaphylaxis and rheumatoid arthritis and further increase in patient preference for autoinjectors drive thegrowth of this treatment segment.
By Type
Disposable Autoinjectors is projected as one of the most lucrative segments.
By Application Segment Review
On the basis of application, the market is categorized into rheumatoid arthritis, multiple sclerosis, anaphylaxis, and others. The anaphylaxis segment held a dominant position in the market, accounting for about 38.5% share of the global autoinjectors market in 2019.
By Application
Anaphylaxis segment holds a dominant position in 2019 and rheumatoid arthritis segment will lead over the forecast period.
By End User Segment Review
By end user, the market is categorized into home care settings and hospitals & clinics. The home care settings segment held a dominant portion in the market, accounting for about 62.8% share of the global autoinjectors market in 2019.
By Region Segment Review
By eegion, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.North America accounted for the largest share in the global autoinjectors market. Asia-Pacific is expected to witness highest growth rate throughout the forecast period. Rise in cases of anaphylaxis; rheumatoid arthritis; and other diseases such as anemia and migraine; and further increase in technological advancements by companies are anticipated to drive the overall market growth.
Competitive Analysis
The major companies profiled in this report includeAmgen, Antares Pharma, Becton Dickinson and Company, Eli Lilly and Company, Johnson and Johnson, Mylan N.V., Novartis AG, SHL Medical, Teva Pharmaceutical Industries Ltd, and Ypsomed AG. Other players in the autoinjectors market (not profiled in the report) include Biogen Idec, Owen Mumford, Consort Medical, Abbvie, and Gerresheimer.
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the global autoinjectors market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers autoinjectors market analysis from 2020to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global autoinjectors market growth.
Key Market Segments
By Type
- Disposable autoinjectors
- Reusable autoinjectors
By Application
- Rheumatoid Arthritis
- Anaphylaxis
- Multiple Sclerosis
- Others
By End User
- Home care settings
- Hospitals & Clinics
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
Autoinjectors Market Report Highlights
| Aspects | Details |
 By TYPE |
|
 By APPLICATION |
|
 By END USER |
|
 By Region |
|
 Key Market Players | ELI LILLY AND COMPANY, NOVARTIS AG, YPSOMED AG, TEVA PHARMACEUTICAL INDUSTRIES LTD., ANTARES PHARMA, SHL MEDICAL AG, JOHNSON & JOHNSON, AMGEN INC., BECTON, DICKINSON, AND COMPANY (BD), MYLAN N.V. |
Analyst Review
An autoinjector is a medical device designed to deliver doses of a particular drug. They are deigned to overcome the phobia of needles and to reduce needle prick pain in patients, especially for those who are undergoing a treatment with frequent injections. Autoinjectors are used for treatment of multiple sclerosis, rheumatoid arthritis, and other diseases such as anemia, migraine, seizures, and few cardiovascular diseases.
The treatments with help of autoinjectors for chronic diseases is anticipated to witness a significant growth. This is attributed to the rise in number of chronic diseases cases, technological advancements by market players and increase in patient preference to opt for self-injections systems. Furthermore, increase in research and development activities by key market players and availability of low cost biosimilars in combination with autoinjectors for treatment of chronic diseases are expected to drive the market growth during the forecast period. Moreover, rise in adoption of autoinjectors by patients for treatment of various diseases is expected to provide lucrative opportunities for the market.
The total value of Autoinjectors market was $ 1,509.0 million in 2019.
The forecast period in the report is from 2020-2027.
The market value of Autoinjectors market in 2020 was $1,790.9 million.
The base year calculated is 2019 in the report.
As per the key industry leaders, rise in incidence of chronic diseases cases , increasing R&D initiatives to develop novel technologies and paradigm shift from biologics to biosimilars will drive the market
Rise in R&D efforts by the key players to develop novel therapies in the market is expected to drive the market growth during the forecast period.
The growth % of the Autoinjectors market is 18.1%.
Disposable autoinjectors segment holds the maximum market share.
Loading Table Of Content...
